ORAGENICS INC
OGEN evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $2.2M
- Lead Asset:
- onp-002 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for OGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OGEN
Oragenics Inc. is a clinical-stage biopharmaceutical company developing intranasal therapeutics for neurological conditions, with its lead candidate ONP-002 targeting concussion and mild traumatic brain injury (mTBI).
Key risk: Capital insufficiency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.2M
Cash Runway
—
Lead Asset
onp-002 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for ORAGENICS INC.
Similar companies
Oragenics Inc. is a clinical-stage biopharmaceutical company developing intranasal therapeutics for neurological conditions, with its lead candidate ONP-002 targeting concussion and mild traumatic brain injury (mTBI).
- Lead candidate ONP-002 is in a Phase IIa clinical trial for concussion/mTBI, with patient enrollment and dosing active in Australia as of May 2026 [news].
- Cash and equivalents were $3.9M as of 2026-06-30, with net income of -$2.5M and shareholders' equity of $3.7M [sec].
- The company expects to need additional capital to complete planned clinical trials, regulatory filings, and any future commercialization efforts [sec_mda · as of 2026-08-13].
- ONP-002, if approved, would be the first pharmacological standard of care for a global concussion market projected to exceed $9 billion by 2030 [sec_mda · as of 2026-05-08].
- Oragenics is listed on the NYSE American under ticker OGEN and continues to provide updates on its clinical and regulatory progress [news].
What works
- ONP-002 addresses a large unmet need in concussion/mTBI, a market projected to reach over $9 billion by 2030, with no FDA-approved pharmacological standard of care currently [sec_mda · as of 2026-05-08].
- The company has a proprietary intranasal delivery platform that targets the brain, potentially offering a differentiated therapeutic approach [news].
- Clinical progress is being made: the Phase IIa trial is active, with multiple sites enrolling patients and dosing underway [news].
What to weigh
- Oragenics is a development-stage company with no approved products and has generated negative net income (-$2.5M as of 2026-06-30) [sec].
- The company faces significant capital requirements and has stated that additional capital is needed to complete planned trials and commercialization; failure to secure funding could delay or eliminate programs [sec_mda · as of 2026-08-13].
- Cash reserves are limited ($3.9M as of 2026-06-30), which may constrain operations and development timelines without near-term financing [sec].
- Any future equity or debt financing could result in dilution or senior claims against the company [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
ONP-002 is in Phase IIa clinical trial for concussion/mTBI
“Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial”
News · August 28, 2026
Additional capital is required to complete planned activities
“Additional capital will still be required to complete planned clinical trials, regulatory filings, and any future commercialization efforts.”
SEC MD&A · August 13, 2026
Concussion market projected to exceed $9 billion by 2030
“ONP-002 would be the first and only pharmacological standard of care for a global concussion market projected to reach over $9 billion by 2030.”
SEC MD&A · May 8, 2026
Risks & what to watch (3)›
Key risks
- Capital insufficiency — The company states additional capital is required to complete trials and commercialization; failure to secure funding could delay or eliminate programs [sec_mda · as of 2026-08-13].
- No approved products — Oragenics is a development-stage company with no approved products and negative net income [sec].
- Shareholder dilution — Raising funds through equity or convertible securities could result in significant dilution to existing shareholders [sec_mda · as of 2026-08-13].
What to watch
- Enrollment and dosing progress in the Phase IIa trial of ONP-002, with updates on patient numbers and site activations [news].
- The company's ability to secure additional financing or strategic partnerships to fund ongoing development [sec_mda · as of 2026-08-13].
- Regulatory milestones, including any FDA interactions or pathway updates for ONP-002 [news].
- NYSE American continued listing status and any corporate updates from the company [news].
Sources: News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run ORAGENICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ORAGENICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.50 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 28, 2026- % of float
- 16.2%
- Days to cover
- 7.2
- Shares short
- 703,470
- Daily short volume (Oct 12, 2026)
- 45.3%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ORAGENICS INC?
Oragenics Inc. is a clinical-stage biopharmaceutical company developing intranasal therapeutics for neurological conditions, with its lead candidate ONP-002 targeting concussion and mild traumatic brain injury (mTBI).
What is ORAGENICS INC's lead drug candidate?
ORAGENICS INC's most advanced tracked candidate is onp-002 (Phase 2) for mild traumatic brain injury ("mTBI" or "concussion").
Who is the CEO of ORAGENICS INC?
Ms. Janet Huffman is the chief executive officer of ORAGENICS INC (OGEN).
Where is ORAGENICS INC headquartered?
ORAGENICS INC (OGEN) is headquartered in Lakewood Ranch, FL, United States.
What therapeutic areas does ORAGENICS INC focus on?
ORAGENICS INC develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.